Our Science

Our science

Cancer cells cunningly evade the immune system using many different mechanisms. We believe that only when the full potential of the human immune system is unleashed, tumors can be effectively treated or even cured. Our main therapeutic approach is to boost anti-tumor immune responses with innate immunity enhancers (I2Es), an emerging class of immuno-oncology (IO) agents. Unlike immune checkpoint inhibitors (ICIs) (also known as anti-PD1/anti-PD-L1 drugs) which activate T cells to kill cancer cells, I2Es activate macrophages and dendritic cells to recognize and destroy cancer cells, providing an alternative mechanism to leverage the immune system to attack tumors, especially "cold tumors" that do not respond to ICIs.

 

Clinical Trials

  • Mavrostobart (PT199) is in a Phase 1/2 clinical trial for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) (the MORNINGSTAR study; ClinicalTrials.gov ID: NCT05431270).
  • Spevatamig (PT886) is in a Phase 1/2 clinical trial for metastatic/advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC), biliary tract cancer (BTC), and PDAC (the TWINPEAK study; ClinicalTrials.gov ID: NCT05482893).
  • Peluntamig (PT217) is in a Phase 1/2 clinical trial for advanced refractory cancers expressing DLL3 (the SKYBRIDGE study; ClinicalTrials.gov ID: NCT05652686).

 

Publications

May 30th, 2026, ASCO:

Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)

April 20th, 2026, AACR:

Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody

Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study

Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapy

 

Expanded Access Policy

Read more about the Expanded Access Policy.